Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: from biological principles to clinical guidelines

Use of Colony-Stimulating Factors With Chemotherapy: Opportunities for Cost Savings and Improved Outcomes

(2011) A. L. Potosky et al.   JNCI-Journal of the National Cancer Institute

Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy

(2010) Gary H. Lyman et al.   CANCER

Prevention of febrile neutropenia in chemotherapy-treated cancer patients: Pegylated versus standard myeloid colony stimulating factors. Do we have a choice?

(2010) Jean Klastersky et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours

(2010) M.S. Aapro et al.   EUROPEAN JOURNAL OF CANCER

Biosimilar agents in oncology/haematology: from approval to practice

(2010) Dietger Niederwieser et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Impact of constitutional polymorphisms in VCAM1 and CD44 on CD34+ cell collection yield after administration of granulocyte colony-stimulating factor to healthy donors

(2010) B. Martin-Antonio et al.   HAEMATOLOGICA

Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients

(2008) Isabel Chirivella et al.   BREAST CANCER RESEARCH AND TREATMENT

Pharmacologic rationale for early G-CSF prophylaxis in cancer patients and role of pharmacogenetics in treatment optimization

(2008) Francesco Crea et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Granulocyte colony-stimulating factor: Molecular mechanisms of action during steady state and ‘emergency’ hematopoiesis

(2008) Athanasia D. Panopoulos et al.   CYTOKINE

Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: Results from an integrated analysis

(2008) G. von Minckwitz et al.   EUROPEAN JOURNAL OF CANCER

Pegfilgrastim   ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study

(2007) G. von Minckwitz et al.   ANNALS OF ONCOLOGY